The report presents an in-depth assessment of the Global Epilepsy Drugs including enabling technologies, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents forecasts for Global Epilepsy Drugs investments from 2020 till 2025.
The major factors for the growth of the epilepsy drugs market include the rise in the new drug approvals over the past few years, increasing cases of epilepsy, and raising awareness about the condition across the globe.
Epilepsy is a central nervous system (CNS) disorder in which brain activity becomes abnormal, resulting in seizures or periods of unusual behavior, and sensations. It can occur due to a genetic disorder or an acquired brain injury. According to the data published by the Epilepsy Foundation, in the United States, in 2015 around 1.2% of the population or 3 million adults had active epilepsy which was an increase from 2.3 million adults with active epilepsy in 2010. Furthermore, as per the data published by the World Health Organization (WHO) epilepsy accounts for a significant proportion of the population affecting around 50 million people worldwide. In addition to the rising cases of epilepsy, there is a rising effort taken to increase awareness about the condition. One of the organization’s Epilepsy Foundation is promoting public awareness and education by undertaking research and delivering specialist medical care and support services to the people affected by epilepsy.
Click the link to get a free Sample Copy of the Report:
Top Leading Manufactures-
Abbott Laboratories, GlaxoSmithKline PLC, Johnson & Johnson Health Care Systems Inc., Novartis AG, Pfizer, Inc., Sanofi SA, Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, UCB S.A.,
Key Market Trends
Second Generation is the Segment by Drugs expected to Hold Largest Market Share over the Forecast Period
The second-generation drugs are expected to hold the largest market share owing to the several significant advantages such as reduced drug-drug interactions, less life-threatening adverse events and less negative impact on cognitive functions. Furthermore, the rising cases of epilepsy will boost the demand for drugs in the market. Also, recently in May 2018 one of the market player UCB announced that the United States Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for its newest anti-epileptic drug (AED) BRIVIACT (brivaracetam) CV oral formulations indicated as monotherapy and adjunctive therapy in the treatment of partial-onset (focal) seizures in patients aged four years and older. Thus, owing to the new product launch and acceptance of second-generation epilepsy drugs the market is expected to witness high growth over the forecast period.
Inquire for Discount:
North America is Expected to Hold Largest Market Share over the Forecast Period
The United States is expected to be the largest epilepsy drug market owing to the presence of better healthcare infrastructure and rising cases of epilepsy. As per the new Morbidity and Mortality Weekly Report from the CDC, around 3.4 million people in the United States live with seizures, including 470,000 children. While, despite all available treatments, 4 out of 10 people with epilepsy continue to experience uncontrolled seizures while many more experience less than optimal seizure control. Thus, there is a rising demand for effective treatment in the region which is expected to boost the growth of the market. Furthermore, there are various organizations making awareness about epilepsy in the United States. For instance, the Epilepsy Foundation is a non-profit organization in the United States, raises public awareness to increase understanding of seizures and dispel myths. Thus, owing to the all above-mentioned factors the market is expected to witness high growth.
What are the market factors that are explained in the report?
–Key Strategic Developments: The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a Global and regional scale.
–Key Market Features: The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.
–Analytical Tools: Global Epilepsy Drugs Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porter’s five forces analysis, feasibility study, and investment return analysis have been used to analyzed the growth of the key players operating in the market.
The research includes historic data from 2014 to 2020 and forecasts until 2025 which makes the reports an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts, and other people looking for key industry data in readily accessible documents with clearly presented tables and graphs.
Media Contact Us:
Irfan Tamboli (Head of Sales) – Market Insights Reports
Phone: + 1704 266 3234 | +91-750-707-8687
firstname.lastname@example.org | email@example.com